These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29487169)

  • 1. Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.
    James B; Chang AD; McTaggart RA; Hemendinger M; Mac Grory B; Cutting SM; Burton TM; Reznik ME; Thompson B; Wendell L; Mahta A; Siket M; Madsen TE; Sheth KN; Nouh A; Furie KL; Jayaraman MV; Khatri P; Yaghi S
    J Neurol Neurosurg Psychiatry; 2018 Aug; 89(8):866-869. PubMed ID: 29487169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.
    Dorado L; Millán M; de la Ossa NP; Guerrero C; Gomis M; López-Cancio E; Ricciardi AC; Dávalos A
    Eur J Neurol; 2010 Feb; 17(2):301-6. PubMed ID: 19912320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
    Mehta RH; Cox M; Smith EE; Xian Y; Bhatt DL; Fonarow GC; Peterson ED;
    Stroke; 2014 Aug; 45(8):2263-9. PubMed ID: 25070958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of early neurological deterioration after I.V - thrombolysis in acute ischaemic stroke patients - A hospital-based cohort study.
    Hansen CK; Christensen A; Havsteen I; Ovesen C; Christensen H
    Clin Neurol Neurosurg; 2018 Aug; 171():58-62. PubMed ID: 29843071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.
    Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
    Amlie-Lefond C; Shaw DWW; Cooper A; Wainwright MS; Kirton A; Felling RJ; Abraham MG; Mackay MT; Dowling MM; Torres M; Rivkin MJ; Grabowski EF; Lee S; Kurz JE; McMillan HJ; Barry D; Lee-Eng J; Ichord RN
    Stroke; 2020 Feb; 51(2):542-548. PubMed ID: 31842706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clotting factors to treat thrombolysis-related symptomatic intracranial hemorrhage in acute ischemic stroke.
    Alderazi YJ; Barot NV; Peng H; Vahidy FS; Navalkele DD; Sangha N; Misra V; Savitz SI
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):e207-14. PubMed ID: 24321775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Etiologies of Early Neurological Deterioration after Thrombolysis and Risk Factors of Ischemia Progression.
    Kim JM; Moon J; Ahn SW; Shin HW; Jung KH; Park KY
    J Stroke Cerebrovasc Dis; 2016 Feb; 25(2):383-8. PubMed ID: 26597264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
    Marsh EB; Gottesman RF; Hillis AE; Urrutia VC; Llinas RH
    Medicine (Baltimore); 2013 Nov; 92(6):317-323. PubMed ID: 24145699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
    Orlando A; Wagner JC; Fanale CV; Whaley M; McCarthy KL; Bar-Or D
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):969-76. PubMed ID: 26856464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
    Chang A; Llinas EJ; Chen K; Llinas RH; Marsh EB
    Stroke; 2018 Jun; 49(6):1521-1524. PubMed ID: 29686025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age.
    Arora R; Salamon E; Katz JM; Cox M; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Smith EE; Schwamm LH; Xian Y; Libman RB
    Stroke; 2016 Sep; 47(9):2347-54. PubMed ID: 27491734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases.
    Shahjouei S; Tsivgoulis G; Bavarsad Shahripour R; Jones GM; Alexandrov AV; Zand R
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2685-93. PubMed ID: 26542821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Tissue Plasminogen Activator in Stroke Mimics.
    Ali-Ahmed F; Federspiel JJ; Liang L; Xu H; Sevilis T; Hernandez AF; Kosinski AS; Prvu Bettger J; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005609. PubMed ID: 31412730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis.
    Bravo Y; Martí-Fàbregas J; Cocho D; Rodríguez-Yáñez M; Castellanos M; de la Ossa NP; Roquer J; Obach V; Maestre J; Martí-Vilalta JL
    Cerebrovasc Dis; 2008; 26(2):126-33. PubMed ID: 18560215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA.
    Shah K; Clark A; Desai SM; Jadhav AP
    Neurocrit Care; 2022 Feb; 36(1):123-129. PubMed ID: 34228264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.